Hypoparathyroidism Drug Pipeline Analysis Report 2025

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone production, which leads to low calcium levels and various symptoms such as muscle cramps and fatigue. The disease affects approximately 23 to 37 cases per 100,000 individuals annually. Current treatment options, including calcium and vitamin D supplements, do not address the underlying cause of the condition, creating a significant unmet clinical need. The growing focus on targeted therapies and novel drug candidates is expected to accelerate the development of hypoparathyroidism therapeutics. In the coming years, advancements in gene therapy and hormone replacement products are likely to enhance pipeline growth and improve patient outcomes.

Report Coverage

The Hypoparathyroidism Drug Pipeline Insight Report by the publisher gives comprehensive insights into hypoparathyroidism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypoparathyroidism. The hypoparathyroidism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypoparathyroidism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypoparathyroidism treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypoparathyroidism.

Hypoparathyroidism Drug Pipeline Outlook

Hypoparathyroidism is a rare endocrine disorder where the parathyroid glands produce insufficient parathyroid hormone (PTH), leading to low calcium and high phosphate levels. This condition can occur due to damage or removal of the parathyroid glands, autoimmune diseases, or genetic mutations. The low calcium levels result in symptoms like muscle spasms, seizures, and fatigue.

Hypoparathyroidism treatment typically involves calcium and vitamin D supplementation to maintain calcium levels. However, these do not address the root cause. Newer therapies include recombinant PTH (1-34) injections, which help restore calcium balance, offering a more effective treatment option for long-term management.

Hypoparathyroidism Epidemiology

The estimated prevalence of hypoparathyroidism is approximately 23 to 37 cases per 100,000 individuals annually. In the United States, the prevalence ranges from 6.4 to 37 per 100,000, with 75% of cases resulting from complications of thyroidectomy or head and neck surgeries. In the United Kingdom, chronic hypoparathyroidism is considered rare, with a prevalence of 37 per 100,000 individuals.

Hypoparathyroidism - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of hypoparathyroidism drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Peptides
• Monoclonal Antibodies
• Gene Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Hypoparathyroidism - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total hypoparathyroidism clinical trials.

Hypoparathyroidism - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hypoparathyroidism pipeline analysis include small molecules, peptides, monoclonal antibodies, and gene therapies. The hypoparathyroidism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypoparathyroidism.

Hypoparathyroidism Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the hypoparathyroidism drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypoparathyroidism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypoparathyroidism clinical trials:

• MBX Biosciences
• Amorphical Ltd.
• Entera Bio Ltd.
• Ascendis Pharma Bone Diseases A/S
• Visen Pharmaceuticals (Shanghai) Co., Ltd.
• AstraZeneca
• Novartis

Hypoparathyroidism Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypoparathyroidism. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypoparathyroidism drug candidates.

Drug: TransCon PTH

The PaTHway China Trial, sponsored by Visen Pharmaceuticals, is a Phase III study investigating the safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism. The primary objective is to assess the treatment effect on serum calcium levels and reduce dependence on active vitamin D and calcium supplements. The study will enroll approximately 76 participants and is expected to be completed by December 2025.

Drug: MBX 2109

The Phase II study, sponsored by MBX Biosciences, aims to evaluate the safety, pharmacokinetics, and efficacy of MBX 2109 in patients with hypoparathyroidism. The objective is to assess if MBX 2109 can maintain normal serum calcium levels without the need for active vitamin D and calcium supplements. The study is expected to be completed by July 2025, with around 48 participants.

Drug: AMOR-1

The Phase II clinical trial, sponsored by Amorphical Ltd., seeks to evaluate the safety and efficacy of AMOR-1 as a treatment for hypocalcemia in adults with hypoparathyroidism. The study will assess whether AMOR-1, containing amorphous calcium carbonate, can replace current calcium supplements. The trial is expected to be completed by September 2026, with an estimated 81 participants enrolled.

Reasons To Buy This Report

The Hypoparathyroidism Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypoparathyroidism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypoparathyroidism collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Hypoparathyroidism - Pipeline Insight Report

• Which companies/institutions are leading the hypoparathyroidism drug development?
• What is the efficacy and safety profile of hypoparathyroidism pipeline drugs?
• Which company is leading the hypoparathyroidism pipeline development activities?
• What is the current hypoparathyroidism commercial assessment?
• What are the opportunities and challenges present in the hypoparathyroidism drug pipeline landscape?
• What is the efficacy and safety profile of hypoparathyroidism pipeline drugs?
• Which company is conducting major trials for hypoparathyroidism drugs?
• Which companies/institutions are involved in hypoparathyroidism collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hypoparathyroidism?

This product will be delivered within 3-5 business days.